Skip to main content
Latest News
September 8, 2026
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
August 29, 2026
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
August 13, 2026
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Latest Events
Event year list
2026
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
October 29, 2026
08:00 AM ET
Bristol Myers Squibb Q3 2026 Results Conference Call
July 30, 2026
08:15 AM ET
Bristol Myers Squibb Q2 2026 Results Conference Call
Webcast
(opens in new window)
Press Release (PDF)
Quarterly Package of Financial Information (XLS)
Q2 2026 Results Presentation (PDF)
Q2 2026 Results Presentation (with Appendix) (PDF)
Preliminary Q2 2026 Acquired IPRD & Licensing Income (PDF)
June 9, 2026
02:00 PM EST
Goldman Sachs 47th Annual Global Healthcare Conference
Webcast
(opens in new window)